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Background-—Once atrial ﬁbrillation (AF) progresses to sustained forms, adverse outcomes increase and treatment success rates
decrease. Therefore, identiﬁcation of risk factors predisposing to persistence of AF may have a signiﬁcant impact on AF morbidity.
Methods and Results-—We prospectively examined the differential associations between traditional, lifestyle, and biomarker AF
risk factors and development of paroxysmal versus nonparoxysmal AF (persistent/permanent) among 34 720 women enrolled in
the Women’s Health Study who were free of cardiovascular disease and AF at baseline. AF patterns were deﬁned based on current
guidelines and classiﬁed according to the most sustained form of AF within 2 years of diagnosis. During a median follow-up of
16.4 years, 690 women developed paroxysmal AF and 349 women developed nonparoxysmal AF. In multivariable time-varying
competing risk models, increasing age (hazard ratio [HR] 1.11, 95% CI 1.10 to 1.13, versus HR 1.08, 1.07 to 1.09, per year), body
mass index (HR 1.07, 1.05 to 1.09, versus HR 1.03, 1.02 to 1.05, per kg/m
2), and weight (HR 1.30, 1.22 to 1.39, versus HR 1.14,
1.08 to 1.20, per 10 kg) were more strongly associated with the development of nonparoxysmal AF compared with paroxysmal AF.
Hemoglobin A1c levels at baseline were directly related to the development of nonparoxysmal AF but inversely associated with
paroxysmal AF in multivariable competing risk models (P for nonequal association=0.01).
Conclusions-—In women without AF or CVD at baseline, increasing age, adiposity, and higher hemoglobin A1c levels were
preferentially associated with the early development of nonparoxysmal AF. These data raise the hypothesis that efforts aimed at
weight reduction or glycemic control may affect the proportion of the population with sustained AF. (J Am Heart Assoc. 2014;3:
e000916 doi: 10.1161/JAHA.114.000916)
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A
trial ﬁbrillation (AF) is a heterogeneous disorder with
variable clinical proﬁle and natural course.
1–3 Experi-
mental models
4,5 have demonstrated the self-perpetuating
nature of AF with recurring episodes becoming more
progressive and eventually sustained. However, in clinical
studies,
6–10 the majority of patients with AF remain paroxys-
mal, suggesting the electrophysiological substrate underlying
AF in those who progress to sustained forms may differ from
that of those who remain paroxysmal. In several studies,
patients who develop these sustained forms of AF (persis-
tent/permanent) also have higher rates of cardiovascular
disease (CVD) morbidity, including cardiovascular hospitaliza-
tions and
7 heart failure
11,12; recent studies suggest that
thromboembolism rates may be higher as well.
7,13 There are
data from recent prospective studies suggesting that patients
who develop sustained forms of AF may have a higher
subsequent mortality.
11,12 It is also well established that
success rates associated with ablative or medical therapies
aimed at maintenance of sinus rhythm are lower once AF
becomes persistent or permanent.
1,14 Therefore, understand-
ing factors that predispose to sustained forms of AF may lead
to preventive and therapeutic approaches that may lower
AF-related morbidity and improve response to traditional
therapies.
Risk factors associated with incident AF have been well
established; however, studies examining whether these AF risk
factors differ with regard to the development of persistent and
permanent AF rather than paroxysmal AF are limited.
6–10,15–17
Prior work has identiﬁed age,
6–8 body mass index (BMI),
9,18
underlying heart disease,
7,8,15 and other comorbidities such as
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ORIGINAL RESEARCHchronic obstructive pulmonary disease and hypertension
(HATCH score)
7,17as risk factors for progression to more
persistent forms of AF among patients with established
paroxysmal AF and varying degrees of CVD. To date, studies
have examined single baseline measures of traditional risk
factors, and data on biomarker associations are lacking. The
majority of studies have been performed in patients with
established paroxysmal AF and varying degrees of CVD, and
data in healthy populations without established AF or CVD
remain sparse.
6,10 Rates of progression to sustained forms of
AF are greatest within the ﬁrst year of diagnosis,
8 suggesting
thateffortsaimedatpreventingsustainedAFmayneedtobegin
before the onset of clinically recognized disease.
To address these gaps, we prospectively examined the
association between AF risk factors and the development of
paroxysmal versus nonparoxysmal AF among a large pro-
spective cohort of women without prior CVD or AF at baseline,
by using traditional and lifestyle risk factors assessed and
updated before the development of AF and using biomarkers
measured at entry into the study before the development of
disease.
Methods
Study Population
All subjects were participants of the Women’s Health Study
(WHS), a previously published,
19,20 randomized placebo-
controlled trial evaluating the beneﬁts and risks of low-dose
aspirin, beta-carotene, and vitamin E in the primary prevention
of CVD and cancer. Brieﬂy, the WHS enrolled 39 876 female
health professionals in 1993 who were 45 years of age or
older without known CVD, cancer, and other major illnesses.
Randomized treatment ended on March 31, 2004, and
subsequently women were invited to participate in continued
observational follow-up. We excluded women who did not
participate in the observational follow-up period (n=4204),
had a history of AF (n=897), or had a conﬁrmed cardiovas-
cular event (n=65) before study entry, leaving 34 720 women
for our primary analysis. Blood samples were available for
28 345 women at the time of randomization. After applying
exclusion criteria, 25 007 were eligible for the biomarker
analyses. The study was approved by the institutional review
board of Brigham and Women’s Hospital, Boston.
Traditional and Lifestyle AF Risk Factors
Information on baseline characteristics, changes in covari-
ates, and study outcomes were collected through the use of
mailed questionnaires at baseline, 6 months, and every
12 months thereafter. Covariates examined include age
(years), BMI (kg/m
2), BMI categories (<25, 25 to 29.9, and
≥30 kg/m
2), weight (per 10 kg), height (per 10 cm), history
of diabetes mellitus, hypertension, hypercholesterolemia, ever
smoker (current and past), alcohol intake (≥2 drinks per day),
and physical activity (<7.5 or ≥7.5 metabolic equivalent hours
per week).
Biomarker Risk Factors
Selected available biomarkers previously associated with AF
in this or other cohorts were analyzed for differential
associations with AF including inﬂammatory markers,
21
hemoglobin (Hb)A1c (%),
22,23 glomerular ﬁltration rate
<60 mL/min per 1.73 m
2,
24,25 and lipids (low- and high-
density lipoproteins and triglycerides [all mg/dL]).
4,26 Based
on prior relationships with AF in this cohort,
21 inﬂammatory
markers, high-sensitivity C-reactive protein, ﬁbrinogen, and
soluble intercellular adhesion molecule were combined into
an inﬂammatory score. The inﬂammatory score ranged from 0
to 3, with 1 point added to the score of a woman for each
marker of inﬂammation in the highest tertile.
21 HbA1c was
analyzed in quartiles.
22
Ascertainment of AF Types
At baseline, 48 months, and annually thereafter, women were
asked to report diagnoses of incident AF. Beginning on
September 19, 2006, additional questionnaires were sent to
women enrolled in the continued observational follow-up who
reported an incident AF event on at least 1 annual question-
naire to conﬁrm AF episodes and collect additional informa-
tion. Available medical records, ECGs, rhythm strips, 24-hour
ECG monitoring, and testing regarding cardiac structure and
function were reviewed. For participants reporting AF during
the trial and observational period who were deceased, family
members were contacted to obtain consent for medical
records. An incident AF event was conﬁrmed if there was ECG
evidence of AF (n=813) or if a medical report clearly indicated
a personal history of AF (n=226). The earliest date in the
medical records was set as the date of onset of AF. An end
point committee of physicians reviewed medical records
according to predeﬁned criteria.
27
AF was classiﬁed into subtypes according to deﬁnitions
recommended by the American College of Cardiology/Amer-
ican Heart Association Task Force on Practice Guidelines and
the European Society of Cardiology Committee for Practice
Guidelines and Policy Conference.
1 Paroxysmal AF was
deﬁned as self-terminating within 7 days, persistent AF
required cardioversion or lasted ≥7 days, and permanent AF
lasted >1 year and/or attempts to convert rhythm were
abandoned.
1 Women with persistent and permanent AF were
categorized together as having nonparoxysmal AF because
physician decision to not pursue cardioversion primarily
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7 To consistently characterize
AF type in women diagnosed with AF early and late in the
study, we assigned the most sustained form (permanent>per-
sistent>paroxysmal) of AF documented in the medical record
within 2 years of initial AF diagnosis.
Statistical Analysis
Person-years of follow-up were calculated from the date
of return of the baseline questionnaire to the ﬁrst occur-
rence of AF, death, loss to follow-up, or March 2, 2011,
whichever came ﬁrst. Women in whom AF pattern could not
be characterized were censored from the analysis at the
time of their AF diagnosis (n=40). Baseline characteristics
across groups of women were compared by using Wilcoxon
rank sum test for continuous variables, v
2 tests for cate-
gorical variables, and Mantel–Haenszel trend test for ordinal
variables.
To evaluate differential relationships for AF risk factors
according to AF type, we used age- and multivariable-adjusted
proportional hazards regression models stratiﬁed by paroxys-
mal and nonparoxysmal AF according to the competing risk
model approach detailed by Lunn and McNeill.
28,29 Through
this method, separate associations of risk factors and their
relative hazards for the 2 AF types are evaluated simulta-
neously under a proportional hazards assumption, which
assumes different associations of each study variable with
paroxysmal and nonparoxysmal AF. To test whether risk
estimates for each individual risk factor differ according to the
2 outcomes, we then ﬁt a series of reduced models in which 1
risk factor at a time was forced to have a single effect
estimate across both outcomes, while the effects of all other
risk factors were allowed to be different. We used likelihood
ratio tests to compare the full competing risk model with the
individual reduced models.
For traditional and lifestyle risk factors, the primary
analysis (n=34 720) consisted of time-varying competing risk
models with updated covariates. The age-adjusted model
further adjusted for aspirin, vitamin E, beta-carotene, BMI,
history of diabetes mellitus, hypertension, hypercholesterol-
emia, ever smoker, alcohol intake, and physical activity. A
second multivariable model (B) substituted height and weight
for BMI and included all covariates in model A. For the
biomarker analyses, we constructed age- and multivariable-
adjusted competing risk models that adjusted for biomarker
levels at baseline, as well as the covariates just described
collected at the time of the baseline blood collection among
25 007 women in the biomarker cohort.
To evaluate the degree to which the association between
risk factors and AF types may be mediated by development of
cardiovascular events (CVE; myocardial infarction, stroke,
revascularization, and heart failure), we reﬁtted competing
risk models to adjust for interim CVE events. We also
performed additional models censoring women at the time
they developed a CVE.
To explore how the presence of symptoms, rate control
medications,
30 or left atrial (LA) enlargement may have
inﬂuenced AF progression and our primary results, we also
examined risk factor associations with nonparoxysmal versus
paroxysmal AF in case-only logistic regression models that
adjusted for symptom status, rate control medications (b-
blocker, calcium channel blockers, or digoxin), and LA
enlargement (LA diameter >40 mm or qualitative description
of enlargement) documented on echocardiogram near the
time of AF diagnosis.
Statistical analysis was performed by using SAS software
version 9.1.3 (SAS Institute Inc). All P values were 2-sided and
statistically signiﬁcant at P≤0.05.
Results
Baseline Characteristics
During a median follow-up of 16.4 years (interquartile range
15.6 to 16.8 years), 1039 conﬁrmed cases of incident AF
occurred. Of those AF cases, 349 (33%) developed nonpar-
oxysmal AF and 690 (67%) remained paroxysmal within
2 years of initial AF diagnosis. Women who developed
nonparoxysmal AF were more likely to be older, heavier,
and obese compared with women with paroxysmal AF. There
were no signiﬁcant differences in other traditional and
lifestyle risk factors among women with paroxysmal and
nonparoxysmal AF (Table 1). With respect to biomarkers,
HbA1c and low-density lipoprotein levels were higher among
women with nonparoxysmal compared with those with
paroxysmal AF (Table 2).
Traditional and Lifestyle Risk Factors and AF Type
In competing risk models, older age and higher BMI were
more strongly associated with nonparoxysmal AF compared
with paroxysmal AF (P<0.001 and P=0.002 for nonequal
association, respectively; Table 3) after adjustment for
updated covariates. For each year of age, the hazard of
developing nonparoxysmal AF increased by 11% (95% CI 10%
to 13%) compared with 8% (95% CI 7% to 9%) for paroxysmal
AF. For BMI, the respective percentage increases were 7%
(95% CI 5% to 9%) versus 3% (95% CI 2% to 5%) for
nonparoxysmal AF versus paroxysmal AF. When compared
with women with a BMI of <25 kg/m
2, obese women
(≥30 kg/m
2) had a 2.56-fold (95% CI 1.93- to 3.40-fold)
higher risk for the development of nonparoxysmal AF versus a
1.49-fold (95% CI 1.22- to 1.83-fold) higher risk for paroxys-
mal AF (P=0.01 for nonequal association). When height and
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Among 34 720 Women in the Primary Analysis
Traditional Lifestyle Factors No AF (N=33 641) Paroxysmal AF (N=690) P Value*
Nonparoxysmal AF
(N=349) P Value
† P Value
‡
Age, median (IQR), y 52.8 (48.8 to 58.5) 57.7 (51.9 to 64.0) <0.001 60.1 (53.8 to 65.5) <0.001 0.001
BMI, median (IQR), kg/m
2 24.9 (22.4 to 28.3) 25.8 (23.2 to 29.8) <0.001 26.6 (23.5 to 31.5) <0.001 0.01
BMI categories, %
<25 kg/m
2 51.4 43.0 34.8
25 to <30 kg/m
2 30.8 33.0 <0.001 32.5 <0.001 0.001
≥30 kg/m
2 17.7 23.9 32.8
Weight, median (IQR), kg 67.6 (59.9 to 77.1) 70.8 (63.5 to 81.6) <0.001 74.8 (63.5 to 86.6) <0.001 0.004
Height, median (IQR), cm 165.1 (160.0 to 167.6) 165.1 (162.6 to 170.2) <0.001 165.1 (162.6 to 170.2) <0.001 0.39
Hypertension, % 24.7 39.4 <0.001 44.8 <0.001 0.09
Diabetes, % 2.4 4.5 <0.001 4.0 0.05 0.72
Hypercholesterolemia, % 29.0 31.7 0.11 37.5 0.001 0.06
Current/past smoking, % 48.3 49.7 0.46 54.7 0.02 0.13
≥2 Alcoholic drinks/day, % 3.9 5.2 0.07 5.7 0.07 0.73
Exercise
<7.5 MET-h per week 45.4 50.3 0.01 47.9 0.36 0.46
≥7.5 MET-h per week 54.6 49.7 52.2
CVD indicates cardiovascular disease; AF, atrial ﬁbrillation; IQR, interquartile range; BMI, body mass index; MET-h, metabolic equivalent hours.
*P value comparing women with paroxysmal AF with women with no AF.
†P value comparing women with nonparoxysmal AF with women with no AF.
‡P value comparing women with paroxysmal AF with women with nonparoxysmal AF.
Table 2. Baseline Biomarker Levels According to the Development of Paroxysmal and Nonparoxysmal AF Among 25 007 Women
Who Donated Blood Samples
Baseline Biomarker No AF (N=24 200) Paroxysmal AF (N=530) P Value* Nonparoxysmal AF (N=277) P Value
† P Value
‡
HbA1c 0.06 <0.001 0.002
≤4.84% 25.4 23.0 15.2
4.84% to ≤5.00% 24.8 22.2 21.7
>5.00% to 5.19% 25.2 28.3 27.4
>5.19% 24.6 26.6 35.7
GFR <60 mL/min per 1.73 m
2, % 5.1 6.4 0.16 9.4 0.001 0.13
Inflammatory score, % <0.001 <0.001
0 39.4 27.5 25.3
1 31.8 32.6 33.7 0.70
2 19.6 25.4 27.1
3 9.2 14.4 13.9
Lipids, median (IQR)
HDL, mg/dL 52.1 (43.3 to 62.5) 51.4 (42.3 to 61.9) 0.30 52.3 (43.4 to 62.8) 0.94 0.61
LDL, mg/dL 121.2 (100.3 to 144.1) 118.9 (99.5 to 144.0) 0.61 128.3 (105.2 to 149.2) 0.01 0.02
Triglycerides, mg/dL 117.0 (83.0 to 173.0) 127.0 (92.0 to 178.0) 0.001 118.0 (86.0 to 181.0) 0.12 0.43
AF indicates atrial ﬁbrillation; HbA1c, hemoglobin A1c; GFR, glomerular ﬁltration rate; IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P value comparing women with paroxysmal AF with women with no AF.
†P value comparing women with nonparoxysmal AF with women with no AF.
‡P value comparing women with paroxysmal AF and women with nonparoxysmal AF.
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Paroxysmal Versus Nonparoxysmal AF Using Updated Covariates Among 34 720 Women in the Primary Analysis
Risk Factor Paroxysmal AF (N=690) P Value
Nonparoxysmal AF
(N=394) P Value P Value*
Model A
Age, per year
Age-adjusted model 1.08 (1.07 to 1.09) <0.001 1.11 (1.09 to 1.12) <0.001
Multivariable-adjusted model 1
† 1.08 (1.07 to 1.09) <0.001 1.11 (1.10 to 1.13) <0.001 <0.001
Multivariable-adjusted model 2
‡ 1.08 (1.06 to 1.09) <0.001 1.11 (1.10 to 1.13) <0.001 <0.001
BMI, per kg/m
2
Age-adjusted model 1.04 (1.03 to 1.06) <0.001 1.08 (1.06 to 1.10) <0.001
Multivariable-adjusted model 1
† 1.03 (1.02 to 1.05) <0.001 1.07 (1.05 to 1.09) <0.001 0.002
Multivariable-adjusted model 2
‡ 1.03 (1.02 to 1.05) <0.001 1.07 (1.05 to 1.09) <0.001 0.003
BMI categories
§
Age-adjusted model
25 to <30 kg/m
2 1.37 (1.14 to 1.63) 0.001 1.57 (1.20 to 2.05) 0.001
>30 kg/m
2 1.71 (1.42 to 2.07) <0.001 2.93 (2.25 to 3.81) <0.001
Multivariable-adjusted model 1
† 0.01
25 to <30 kg/m
2 1.30 (1.08 to 1.55) 0.005 1.51 (1.15 to 1.97) 0.003
>30 kg/m
2 1.49 (1.22 to 1.83) <0.001 2.56 (1.93 to 3.40) <0.001
Multivariable-adjusted model 2
‡ 0.01
25 to <30 kg/m
2 1.30 (1.08 to 1.55) 0.005 1.51 (1.15 to 1.97) 0.003
>30 kg/m
2 1.50 (1.22 to 1.84) <0.001 2.57 (1.93 to 3.40) <0.001
Diabetes
Age-adjusted model 1.52 (1.19 to 1.95) 0.001 1.86 (1.36 to 2.55) <0.001
Multivariable-adjusted model 1
† 1.21 (0.93 to 1.56) 0.15 1.26 (0.96 to 1.76) 0.17 0.84
Multivariable-adjusted model 2
‡ 1.15 (0.89 to 1.50) 0.28 1.22 (0.87 to 1.70) 0.25 0.80
Hypertension
Age-adjusted model 1.66 (1.41 to 1.96) <0.001 2.03 (1.58 to 2.60) <0.001
Multivariable-adjusted model 1
† 1.49 (1.25 to 1.77) <0.001 1.59 (1.23 to 2.06) 0.001 0.66
Multivariable-adjusted model 2
‡ 1.46 (1.23 to 1.74) <0.001 1.57 (1.21 to 2.04) 0.001 0.66
Hypercholesterolemia
Age-adjusted model 0.97 (0.83 to 1.13) 0.69 0.91 (0.73 to 1.13) 0.40
Multivariable-adjusted model 1
† 0.87 (0.75 to 1.02) 0.10 0.78 (0.63 to 0.98) 0.03 0.43
Multivariable-adjusted model 2
‡ 0.86 (0.73 to 1.00) 0.06 0.77 (0.62 to 0.96) 0.02 0.43
Drinks >2 per day
Age-adjusted model 1.28 (0.92 to 1.76) 0.14 1.42 (0.92 to 2.19) 0.11
Multivariable-adjusted model 1
† 1.35 (0.97 to 1.88) 0.07 1.55 (1.00 to 2.40) 0.05 0.63
Multivariable-adjusted model 2
‡ 1.36 (0.98-1.88) 0.07 1.55 (1.00-2.41) 0.05 0.63
Current or past smoker
Age-adjusted model 1.05 (0.90 to 1.22) 0.54 1.29 (1.04 to 1.59) 0.02
Multivariable-adjusted model 1
† 1.03 (0.89 to 1.20) 0.68 1.27 (1.03 to 1.58) 0.03 0.12
Multivariable-adjusted model 2
‡ 1.03 (0.89 to 1.20) 0.73 1.27 (1.02 to 1.57) 0.03 0.12
Exercise, >7.5 MET-h per week
Age-adjusted model 0.91 (0.78 to 1.06) 0.23 0.83 (0.67 to 1.02) 0.07
Continued
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(Table 3, model B), only heavier weight was more strongly
associated with the development of nonparoxysmal AF
(P=0.001 for nonequal association). Taller height was equally
associated with the development of paroxysmal and nonpar-
oxysmal AF.
Interim development of CVE (n=2152) was equally
associated with the subsequent development of AF subtypes
(HR 1.75, 95% CI 1.29 to 2.37 [paroxysmal] vs HR 1.60, 95%
CI 1.07 to 2.40 [nonparoxysmal]; P=0.74 for nonequal
association). In multivariable models adjusting for interim
CVE, the differential relationships persisted for age, BMI, and
weight (Table 3, model 2). When women were censored at
the time of the development of CVD, the differential
relationships for age, BMI, and weight were similar
(P<0.001, P=0.001, and P=0.001 for nonequal association,
respectively).
We then examined the sensitivity of these results to the
presence or absence of symptoms, rate control medications,
or LA enlargement at the time of the AF diagnosis using
case-only logistic regression models. Among 940 women
who developed AF, age (OR 1.04, 95% CI 1.02 to 1.06) and
BMI (OR 1.04, 95% CI 1.02 to 1.07) were signiﬁcantly
associated with nonparoxysmal AF after controlling for
symptom status and rate control medications. The relation-
ship between BMI and nonparoxysmal AF was attenuated
and became nonsigniﬁcant (OR 1.02, 95% CI 0.99 to 1.05) in
models additionally controlling for LA enlargement, whereas
the association with age remained signiﬁcant (OR 1.03, 95%
CI 1.01 to 1.05).
Biomarkers and AF Type
After adjustment for other baseline biomarkers and traditional
risk factors, increasing quartiles of baseline HbA1c level were
associated with increasing risks for the early development of
nonparoxysmal AF and lower risks of paroxysmal AF (P=0.01
for nonequal association, Table 4, model 1). These differential
relationships persisted after censoring women who developed
incident CVE over the course of the study (Table 4, model 2)
and after eliminating diabetic subjects and women with
HbA1c >5.66 (n=1340) from the analysis (P=0.01 for
nonequal association). None of the other biomarkers tested
exhibited signiﬁcant differential associations with paroxysmal
versus nonparoxysmal AF. In these models controlling for
biomarkers, relationships for traditional and lifestyle risk
factors were similar to the updated models, except for age,
which was no longer signiﬁcantly associated with paroxysmal
versus nonparoxysmal AF after controlling for Hba1c (P=0.10
for nonequal association). HbA1c remained signiﬁcantly
associated with nonparoxysmal AF (OR 1.32, 95% CI 1.10 to
1.58) after adjustment for symptom status, rate control
medications, and LA enlargement in a case-only multivariable
logistic regression model.
Discussion
Inthislarge,prospectivecohortstudy,wefoundthatincreasing
age,adiposity,andhigherHbA1clevelsweredifferentiallyasso-
ciated with the development of nonparoxysmal AF compared
Table 3. Continued
Risk Factor Paroxysmal AF (N=690) P Value
Nonparoxysmal AF
(N=394) P Value P Value*
Multivariable-adjusted model 1
† 1.02 (0.87 to 1.19) 0.81 1.02 (0.82 to 1.27) 0.87 1.00
Multivariable-adjusted model 2
‡ 1.03 (0.88 to 1.20) 0.73 1.03 (0.83 to 1.28) 0.81 1.00
Model B
k
Height, per 10 cm
Age-adjusted model 1.34 (1.19 to 1.52) <0.001 1.40 (1.18 to 1.67) <0.001
Multivariable-adjusted model 1
† 1.38 (1.22 to 1.57) <0.001 1.42 (1.19 to 1.70) <0.001 0.78
Multivariable-adjusted model 2
‡ 1.38 (1.22 to 1.57) <0.001 1.43 (1.20 to 1.70) <0.001 0.78
Weight, per 10 kg
Age-adjusted model 1.18 (1.12 to 1.23) <0.001 1.35 (1.27 to 1.43) <0.001
Multivariable-adjusted model 1
† 1.14 (1.08 to 1.20) <0.001 1.30 (1.22 to 1.39) <0.001 0.001
Multivariable-adjusted model 2
‡ 1.14 (1.08 to 1.20) <0.001 1.31 (1.22 to 1.39) <0.001 0.001
CVD indicates cardiovascular disease; AF, atrial ﬁbrillation; BMI, body mass index; MET-h, metabolic equivalent hours.
*P value from likelihood ratio tests of the null hypothesis that a risk factor has an equal effect on development of paroxysmal vs nonparoxysmal AF.
†Model 1: additionally adjusted for aspirin, vitamin E, beta-carotene, BMI, hypertension, diabetes, cholesterol, alcohol consumption, smoking, and exercise, using time-varying covariates.
‡Model 2: additionally adjusted for interim development of myocardial infarction, stroke, revascularization, and heart failure using time-varying covariates.
§Hazard ratios are for categories; however, likelihood ratio tests are based on comparison of models that use continuous values.
kModel B: adjusted for height and body weight using time-varying covariates instead of BMI.
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HTable 4. Age- and Multivariable-Adjusted Hazard Ratios (95% CI) for Development of Paroxysmal Versus Nonparoxysmal AF
According to Baseline Levels of Biomarkers Among 25 007 Women Who Donated Blood Samples
Risk Factor Paroxysmal AF (N=530) P Value
Nonparoxysmal AF (N=
277) P Value P Value*
HbA1c
†
Age-adjusted model
4.84% to <5.00% 0.89 (0.69 to 1.15) 0.38 1.29 (0.87 to 1.91) 0.21
>5.00% to 5.19% 1.02 (0.80 to 1.30) 0.87 1.44 (0.98 to 2.10) 0.06
>5.19% 0.91 (0.71 to 1.16) 0.44 1.74 (1.20 to 2.50) 0.003
Multivariable-adjusted model 1
‡ 0.01
4.84% to <5.00% 0.88 (0.68 to 1.14) 0.32 1.27 (0.84 to 1.90) 0.26
>5.00% to 5.19% 0.96 (0.75 to 1.23) 0.73 1.39 (0.94 to 2.06) 0.10
>5.19% 0.78 (0.60 to 1.01) 0.06 1.47 (1.00 to 2.18) 0.05
Multivariable-adjusted model 2
§
4.84% to <5.00% 0.90 (0.69 to 1.17) 0.42 1.30 (0.85 to 1.97) 0.22 0.01
>5.00% to 5.19% 0.99 (0.77 to 1.27) 0.93 1.43 (0.96 to 2.15) 0.08
>5.19% 0.76 (0.58 to 1.00) 0.05 1.48 (0.98 to 2.22) 0.06
GFR, <60 mL/min per 1.73 m
2
Age-adjusted model 1.08 (0.74 to 1.57) 0.69 1.57 (1.02 to 2.42) 0.04
Multivariable-adjusted model 1
‡ 1.21 (0.82 to 1.78) 0.35 1.56 (0.99 to 2.47) 0.06 0.40
Multivariable-adjusted model 2
§ 1.05 (0.68 to 1.60) 0.84 1.31 (0.79 to 2.17) 0.29 0.51
Inflammation score
†
Age-adjusted model
1 1.26 (1.01 to 1.58) 0.04 1.33 (0.97 to 1.83) 0.07
2 1.49 (1.17 to 1.89) 0.001 1.61 (1.15 to 2.24) 0.01
3 1.87 (1.41 to 2.47) <0.001 1.84 (1.24 to 2.74) 0.003
Multivariable-adjusted model 1
‡ 0.27
1 1.17 (0.93 to 1.47) 0.18 1.15 (0.84 to 1.59) 0.38
2 1.31 (1.02 to 1.70) 0.04 1.14 (0.80 to 1.63) 0.47
3 1.51 (1.11 to 2.07) 0.009 1.14 (0.73 to 1.78) 0.56
Multivariable-adjusted model 2
§ 0.28
1 1.23 (0.97 to 1.55) 0.09 1.16 (0.83 to 1.61) 0.39
2 1.31 (1.00 to 1.71) 0.05 1.16 (0.80 to 1.68) 0.42
3 1.51 (1.09 to 2.10) 0.01 1.10 (0.69 to 1.75) 0.79
Lipids
HDL, mg/dL
Age-adjusted model 0.84 (0.67 to 1.05) 0.12 0.91 (0.67 to 1.24) 0.57
Multivariable-adjusted model 1
‡ 1.04 (0.81 to 1.35) 0.74 1.15 (0.81 to 1.63) 0.43 0.66
Multivariable-adjusted model 2
§ 1.07 (0.83 to 1.40) 0.59 1.19 (0.83 to 1.71) 0.34 0.65
LDL, mg/dL
Age-adjusted 0.87 (0.79 to 0.96) 0.01 1.01 (0.88 to 1.15) 0.94
Multivariable-adjusted model 1
‡ 0.83 (0.74 to 0.93) 0.001 0.92 (0.79 to 1.06) 0.25 0.29
Multivariable-adjusted model 2
§ 0.82 (0.74 to 0.92) 0.001 0.94 (0.80 to 1.10) 0.41 0.19
Triglycerides, mg/dL
Age-adjusted model 1.06 (0.99 to 1.15) 0.12 1.01 (0.90 to 1.13) 0.89
Continued
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at baseline. There was a signiﬁcant graded-risk relationship
between these risk factors and the development of persistent
or chronic AF within 2 years after initial AF diagnosis, which
was signiﬁcantly stronger than that observed for paroxysmal
AF. In the case of hemoglobin A1c, the directionality of the
association differed as well. These differential associations
did not appear to be mediated by the subsequent develop-
ment of CVD, which was equally associated with the
development of nonparoxysmal and paroxysmal AF in this
healthy cohort.
Rates of progression to sustained forms of AF among
patients with paroxysmal AF appear to be greatest within the
ﬁrst year,
8 with estimates ranging from 8.6% to 15%.
7,8,30
Using deﬁnitions in accordance with current guidelines, one
third of woman in our study either present with or develop
nonparoxysmal AF within 2 years of their incident AF
diagnosis, suggesting that for many patients efforts aimed
at preventing sustained AF may need to begin early.
Increasing age and established CVD have been consis-
tently associated with the development of sustained forms of
AF among patients with established AF.
7,8,15 A longitudinal
cohort study
9 and case-control study
18 also found a linear
relationship between a single measure of BMI and progression
and sustained forms of AF among patients with a higher
burden of CVD. Our study suggests both increasing age and
adiposity are preferentially associated with the early devel-
opment of nonparoxysmal AF even among relatively healthy
populations without established AF, and these differential
relationships are not mediated through the development of
CVE. The strong association between updated measures of
BMI and nonparoxysmal AF also raises the possibility that
dynamic changes in BMI might be expected to inﬂuence risk
for the development of sustained forms of AF.
31
Experimental
32,33 and clinical studies
9,34,35 have provided
several possible mechanisms for the underlying relationship
between adiposity and AF susceptibility. Obesity has been
associated with the development of diastolic dysfunction
leading to an increased LA pressure and enlargement,
9,35
which in turn leads to neurohormonal activation, atrial stretch,
and ﬁbrosis, all of which can result in an atrial substrate
facilitating the maintenance of AF.
9,34,35Weight gain also
results in myocardial lipid deposition and inﬂammatory
inﬁltrates in atrial tissue in experimental models, which
contribute to further electrostructural remodeling and
increased AF burden.
32 The results of our case-only analysis
are consistent with the hypothesis that LA enlargement and/
or 1 of these processes that accompany LA enlargement
mediate at least part of the association between obesity and
nonparoxysmal AF.
The differential association between HbA1c and AF
subtypes in our population of healthy women is a novel
ﬁnding. Our data suggest that a strong positive relationship
exists between HbA1c and the development of nonparoxys-
mal AF, whereas an inverse relationship exists for paroxysmal
AF. These relationships persisted even among women without
overt clinical or undiagnosed prediabetes. The positive
association for nonparoxysmal AF and the inverse association
for paroxysmal AF suggest that hyperglycemia, concomitant
insulin resistance, or other associated unmeasured metabolic
abnormalities may inﬂuence AF risk primarily through mech-
anisms involved in maintenance rather than initiation of AF.
The observed differential association between HbA1c and AF
subtypes might also provide an explanation for the apparently
discrepant ﬁndings regarding the association among diabetes,
glycemic control, and incident AF risk in previous stud-
ies.
16,22,23,36,37 Associations may vary depending on the
degree of glycemic control among diabetic patients and may
relate to the proportion of incident AF cases that are
paroxysmal and nonparoxysmal in each cohort.
In contrast to earlier work among patients with established
AF, we did not ﬁnd a differential association between
hypertension and AF types in our female subjects without
established AF. This may be partly explained by the different
study populations. The female health professionals in our
study may have had been more aggressively treated for
hypertension than the general population of patients with AF
enrolled in the Euro Heart Survey.
7 Consistent with this
possibility, a case-control study
17 performed among hyper-
tensive patients found the average systolic blood pressure
Table 4. Continued
Risk Factor Paroxysmal AF (N=530) P Value
Nonparoxysmal AF (N=
277) P Value P Value*
Multivariable-adjusted model 1
‡ 1.02 (0.93 to 1.11) 0.74 0.90 (0.79 to 1.03) 0.14 0.15
Multivariable-adjusted model 2
§ 1.02 (0.93 to 1.12) 0.68 0.91 (0.79 to 1.05) 0.20 0.18
AF indicates atrial ﬁbrillation; HbA1c, hemoglobin A1c; GFR, glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P values from likelihood ratio tests of the null hypothesis that a risk factor has an equal effect on development of paroxysmal vs nonparoxysmal AF based on trend.
†Hazard ratios are for categories; however, likelihood ratio tests are based on comparison of models that use continuous trend values.
‡Model 1: additionally adjusted for aspirin, vitamin E, beta-carotene, body mass index, hypertension, cholesterol, alcohol consumption, smoking and exercise, inﬂammation score, HBA1c,
GFR, and lipids assessed at baseline (n=24 392 women due to missing data in the blood cohort).
§Model 2: censored for interim myocardial infarction, stroke, revascularization, and heart failure (n=24 392 women due to missing data in the blood cohort).
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Hachieved on treatment was more strongly associated with
sustained rather than nonsustained forms of AF.
Strengths and Limitations
This study has several strengths, including the prospective
design, large number of participants with long follow-up,
updated measures of traditional variables, and medical record
conﬁrmation of AF pattern according to current guidelines.
There are also several limitations of the present study, which
warrant discussion. First, the study included relatively healthy,
middle-aged, white female health professionals and results
may not be generalizable to other populations. Second,
traditional risk factor assessments were based on self-report,
which may lead to nondifferential misclassiﬁcation and could
have biased results toward the null. However, high correla-
tions have been demonstrated between self-reported and
directly measured variables such as weight (r=0.96) and BMI
in comparable cohorts.
38,39 Third, AF detection and classiﬁ-
cation of AF pattern over time can be challenging without
continuous ECG monitoring, which is impractical in free living
cohort studies. Thus, some degree of misclassiﬁcation of AF
pattern resulting from underdetection likely exists due to
asymptomatic episodes of AF in this cohort. However, the
differential associations with AF subtypes persisted for age,
BMI, and HbA1c in case-only analyses controlling for symp-
tom status at the time of AF diagnosis. Fourth, because we
limited our evaluation of AF pattern to the time period within
2 years of AF diagnosis, these data may not be able to be
extrapolated to later time points. Fifth, standardized echocar-
diograms were not systematically collected in this cohort,
and therefore, we were unable to perform a formal mediation
analysis. Sixth, biomarker measurements were available only
at baseline, and therefore, we could not evaluate whether
dynamic changes in HbA1c or other biomarkers over time
were differentially associated with the development of
paroxysmal and nonparoxysmal AF. Last, due to the obser-
vational nature of the study, we cannot exclude the possibility
that residual or unmeasured confounding may have accounted
for part of the associations observed.
These prospective data suggest increasing age, adiposity,
and higher HbA1c levels are preferentially associated with the
early development of nonparoxysmal AF among a cohort of
middle-aged women without previous cardiovascular disease.
These data raise the hypothesis that early efforts aimed at
weight reduction or glycemic control in the general popula-
tion, before the development of AF, might have a signiﬁcant
impact on the proportion of individuals who develop sustained
forms of AF. Given the considerable health care costs,
40
adverse outcomes,
7,12,13 and limited long-term success
rates
14 associated with the treatment of persistent AF once
established, the potential to reduce the proportion of
individuals who develop sustained forms of AF through early
preventive efforts is appealing and warrants further study.
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